Entrada Therapeutics, Inc. (NASDAQ: TRDA) is a Healthcare company (Biotechnology) with a market capitalization of $194M. The Maz Rating grades it against the other companies in its sector.
Entrada Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.96, Entrada Therapeutics, Inc. trades at 53.3x sales and 1.2x book value. Over the last twelve months it generated about $4M of revenue and a net loss of $138M. It runs a gross margin of 57.5%, an operating margin of -4303.8% and a net margin of -4058.0%. It shows return on equity of -64.0%, return on invested capital of -69.7% and a free cash flow yield of -70.2%. On the balance sheet: a debt-to-equity ratio of 0.24 and a current ratio of 7.85. Over the past 52 weeks the share price ranged from $4.11 to $16.45, with a beta of -0.24.
Entrada Therapeutics, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 4 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.